Name: Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay (Video) | JoVE Journal
Uploaded: 2021-02-09T13:30:00.000+00:00
Duration: 5 min 17 s
Description: Learn solid phase synthesis of spirocyclic heterocycles and cytotoxicity assessment using MTT assay on COS7 cells. This method evaluates novel compounds for cancer drug development.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work was funded by a grant from the Faculty Research Council to K.S.H. (Office of Research and Grants, Azusa Pacific University-USA). A.N.G. and J.F.M. are recipients of the Scholarly Undergraduate Research Experience (SURE) Fellowship. S.K.M. and B.M.R. are recipients of the STEM Research Fellowship Grants (Center for Research in Science, Azusa Pacific University-USA). We are grateful to Dr. Matthew Berezuk and Dr. Philip Cox for guidance on the bioassays.

NOTE: Several chemicals and biological reagents used in this protocol are toxic and carcinogenic. Consult relevant material safety data sheets (MSDS) prior to use. Use appropriate personal protective gears (Occupational Safety and Health Administration-approved safety goggles, proper gloves, lab coats, full-length pants, and closed-toe shoes) prior to starting the experiment. In addition, adopt appropriate safety practices when performing synthesis and handling toxic chemicals and reagents (fume hood).
1. Solid phase synthesis of spirocyclic heterocycles 6 and 7
NOTE: Synthesis was based on previously published work11,12. The updated protocol reveals that the tetrabutylammonium fluoride-catalyzed ring opening of the tricyclic heterocycle was not needed, and thus its elimination shortens the synthetic procedure.
<ol>
	<li>Perform Michael addition of furfurylamine to the REM linker (duration: 25 min setup + 24 h reaction time).
	<ol>
		<li>Add 1 g (1 equivalents [equiv.]) of REM resin, 20 mL (20 equiv.) of dimethylformamide (DMF), and 2.4 mL of furfurylamine to a 25 mL solid-phase reaction vessel. Agitate the reaction vessel at room temperature for 24 h following the reaction initiation. 
		NOTE: Ensure thorough mixing so that the resin does not sit at the bottom of the vessel.</li>
		<li>Wash the resin with DMF 1x after the reaction is complete. Then, wash 4x, alternating between dichloromethane (DCM) and methanol. Dry the resin thoroughly in the reaction vessel following washes.</li>
	</ol>
	</li>
	<li>Perform tandem Michael addition/1,3-dipolar cycloaddition (duration: 25 min setup + 48 h reaction time).
	<ol>
		<li>To the dry resin, add 1.48 mL (5 equiv.) of triethylamine (TEA), 0.637 g (2 equiv.) of nitro-olefin, and 10 mL of dry toluene to the reaction vessel.</li>
		<li>Then, add 1.085 mL (4 equiv.) of trimethylsilyl chloride (TMSCl) to the reaction vessel in a well-ventilated fume hood. 
		NOTE: As this reaction produces HCl gas, do not cap the reaction vessel until the gas has been released under a fume hood.</li>
		<li>Securely cap the reaction vessel, and agitate at room temperature for 48 h. 
		NOTE: Ensure thorough mixing of the resin with the reagents.</li>
		<li>Use 5 mL of methanol to quench the reaction.</li>
		<li>Drain the vessel to remove the solution, and then wash 4x, alternating between DCM and methanol. Dry the resin thoroughly in the reaction vessel following washes.</li>
	</ol>
	</li>
	<li>Perform N-alkylation of the resin-bound heterocycle to form the quaternary amine (duration: 10 min setup + 24 h reaction time).
	<ol>
		<li>To the dry resin in the reaction vessel, add 5 mL of DMF and 10 equiv. of alkyl halide, and agitate at room temperature for 24 h. 
		NOTE: Ensure thorough mixing of the reagents with the resin.</li>
		<li>Wash the resin with DMF 1x after the reaction is complete. Then, use DCM and methanol alternately to wash 4x. Dry the resin in the reaction vessel following washes.</li>
	</ol>
	</li>
	<li>Perform &#946;-elimination of the quaternary amine for cleavage from the polymer support (duration: 15 min setup + 24 h reaction time).
	<ol>
		<li>To the dry resin in the reaction vessel, add 3 mL of DCM and 1.49 mL (5 equiv.) of TEA to cleave the heterocycle from the polymer support.</li>
		<li>Agitate the reaction mixture for 24 h to ensure thorough mixing of the resin with the solution. Wash 4x, alternating between DCM and methanol. Collect the elution from all the washes, and concentrate via rotatory evaporation.</li>
		<li>Triturate with methanol to purify the spirocyclic oxime. Dry the resin thoroughly in the reaction vessel following washes for reuse in future experiments.</li>
	</ol>
	</li>
</ol>
2. Cytotoxicity assay using MTT 14
<ol>
	<li>Prepare 20 mL of a 5 mg/mL MTT solution using sterile phosphate-buffered saline (PBS, 0.9% NaCl in water) as the diluent. Filter and store at -20 &#176;C. Then, prepare a 1:1 dilution of the MTT solution from step 2.1 in serum-free cell culture medium (DMEM).</li>
	<li>Prepare 1 mL each of stock solutions in 1.5 mL microcentrifuge tubes of 100 mM, 10 mM, 1 mM, 100 &#181;M, 10 &#181;M, 1 &#181;M, 0.1 &#181;M, and 0.01 &#181;M of test compounds in dimethyl sulfoxide (DMSO). Store at -20 &#176;C. Prepare 200 &#181;L per dose of the working solutions of test compounds by diluting stock concentrations 1:1000 in serum-free medium in 1.5 mL tubes.</li>
	<li>In the tissue culture hood, seed COS-7 cells (African green monkey kidney cells, Cercopithecus aethiops kidney) in complete medium [DMEM with 10% fetal bovine serum (FBS)] onto flat-bottom, tissue-culture-treated 96-well plates at a concentration of 4 &#215; 103 cells/200 &#181;L per well using a multi-channel pipettor. COS-7 cells were chosen because (1) these are commonly used cells for cytotoxicity assays and (2) these were already available in the institution.</li>
	<li>Incubate COS-7 cells for 24 h at 37 &#176;C in an atmosphere containing 5% CO2.</li>
	<li>Aspirate the supernatant from the wells using a glass Pasteur pipette attached to a vacuum pump. Dose the cells in triplicate with the test compounds using the working solutions prepared in step 2.2 (See Table 1). Incubate cells as described in step 2.4.</li>
	<li>Aspirate the supernatant from the wells. Add 200 &#181;L of MTT solution to each well. Incubate at 37 &#176;C in an atmosphere containing 5% CO2 for 4 h.</li>
	<li>Gently aspirate the supernatant from the wells without disturbing the purple formazan crystals. Add 200 &#181;L of DMSO to each well to dissolve the purple formazan crystals. Incubate at room temperature for 15 min.</li>
	<li>Measure absorbance at 590 nm14 or 600 nm for each well using a 96-well plate reader. Use wells with no cells as background and average the absorbance value. Subtract the averaged absorbance background value from the absorbance value of each treated well. Normalize the data as a percentage of the average zero dosage value (average the three zero-dose values). Plot data on the y-axis: linear (% relative cell viability); x-axis: log (concentration). Plot each series as an individual curve (e.g., triplicate data should have 3 curves)</li>
</ol>

<ol><li>Shangary, S., Wang, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Small-molecule+inhibitors+of+the+MDM2-p53+protein-protein+interaction+to+reactivate+p53+function%3A+a+novel+approach+for+cancer+therapy%5BTitle%5D)+AND+%22Annual+Review+of+Pharmacology+and+Toxicology%22%5BJournal%5D)">Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.</a> Annual Review of Pharmacology and Toxicology. 49, 223-241 (2009).</li>
<li>Zhao, Y., Aguilar, A., Bernard, D., Wang, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Small-molecule+inhibitors+of+the+MDM2-p53+protein-protein+interaction+%28MDM2+inhibitors%29+in+clinical+trials+for+cancer+treatment%5BTitle%5D)+AND+%22Journal+of+Medicinal+Chemistry%22%5BJournal%5D)">Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment.</a> Journal of Medicinal Chemistry. 58 (3), 1038-1052 (2015).</li>
<li>Paolo, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+effective+virtual+screening+protocol+to+identify+promising+p53-MDM2+inhibitors%5BTitle%5D)+AND+%22Journal+of+Chemical+Information+and+Modeling%22%5BJournal%5D)">An effective virtual screening protocol to identify promising p53-MDM2 inhibitors.</a> Journal of Chemical Information and Modeling. 56 (6), 1216-1227 (2016).</li>
<li>Shieh, S. Y., Ikeda, M., Taya, Y., Prives, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((DNA+damage-induced+phosphorylation+of+p53+alleviates+inhibition+by+MDM2%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.</a> Cell. 91 (3), 325-334 (1997).</li>
<li>Hwang, B. J., Ford, J. M., Hanawalt, P. C., Chu, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Expression+of+the+p48+xeroderma+pigmentosum+gene+is+p53+dependent+and+is+involved+in+global+genomic+repair%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22%5BJournal%5D)">Expression of the p48 xeroderma pigmentosum gene is p53 dependent and is involved in global genomic repair.</a> Proceedings of the National Academy of Sciences of the United States of America. 96 (2), 424-428 (1999).</li>
<li>Oliner, J. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Oncoprotein+MDM2+conceals+the+activation+domain+of+tumor+suppressor+p53%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53.</a> Nature. 362, 857-860 (1993).</li>
<li>Nag, S., Qin, J., Srivenugopal, K. S., Wang, M., Zhang, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+MDM2-p53+pathway+revisited%5BTitle%5D)+AND+%22Journal+of+Biomedical+Research%22%5BJournal%5D)">The MDM2-p53 pathway revisited.</a> Journal of Biomedical Research. 27 (4), 254-271 (2013).</li>
<li>Bond, G. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+single+nucleotide+polymorphism+in+the+MDM2+promoter+attenuates+the+p53+tumor+suppressor+pathway+and+accelerates+tumor+formation+in+humans%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.</a> Cell. 119 (5), 591-602 (2004).</li>
<li>Isobe, M., Emanuel, B. S., Givol, D., Oren, M., Croce, C. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Localization+of+gene+for+human+p53+tumor+antigen+to+band+17p13%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Localization of gene for human p53 tumor antigen to band 17p13.</a> Nature. 320 (6057), 84-85 (1986).</li>
<li>Gupta, A. K., Bharadwaj, M., Kumar, A., Mehrotra, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Spiro-oxindoles+as+a+promising+class+of+small+molecules+inhibitors+of+p53-MDM2+interaction+useful+in+targeted+cancer+therapy%5BTitle%5D)+AND+%22Topics+in+Current+Chemistry%22%5BJournal%5D)">Spiro-oxindoles as a promising class of small molecules inhibitors of p53-MDM2 interaction useful in targeted cancer therapy.</a> Topics in Current Chemistry. 375 (1), 1-25 (2017).</li>
<li>Griffin, S. A., Drisko, C. R., Huang, K. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Tricyclic+heterocycles+as+precursors+to+functionalized+spirocyclic+oximes%5BTitle%5D)+AND+%22Tetrahedron+Letters%22%5BJournal%5D)">Tricyclic heterocycles as precursors to functionalized spirocyclic oximes.</a> Tetrahedron Letters. 58, 4551-4553 (2017).</li>
<li>Drisko, C. R., Griffin, S. A., Huang, K. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Solid-phase+synthesis+of+%5B4.4%5Dspirocyclic+oximes%5BTitle%5D)+AND+%22Journal+of+Visualized+Experiments%22%5BJournal%5D)">Solid-phase synthesis of [4.4]spirocyclic oximes.</a> Journal of Visualized Experiments. (144), e58508(2019).</li>
<li>Lawrence, N. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Linked+parallel+synthesis+and+MTT+bioassay+screening+of+substituted+chalcones%5BTitle%5D)+AND+%22Journal+of+Combinatorial+Chemistry%22%5BJournal%5D)">Linked parallel synthesis and MTT bioassay screening of substituted chalcones.</a> Journal of Combinatorial Chemistry. 3 (5), 421-426 (2001).</li>
<li>MTT assay protocol. , Modified procedure from 
 .
 (2020).</li>
</ol>

The authors have nothing to disclose.

The synthesis of the spirocyclic compounds was based on previous research conducted by this laboratory, but with some modifications (Figure 1)11,12. The progress of each reaction step was monitored by IR spectroscopy. Michael addition of the REM linker&#160;1&#160;with furfurylamine afforded polymer-bound&#160;2&#160;(IR 1722 cm-1&#160;&#8594; 1731 cm-...

Small-molecule inhibition of the interaction of E3 ubiquitin-ligase mouse double minute 2 homolog (MDM2) with p53 is known to restore p53-mediated induction of tumor cell apoptosis1,2,3. MDM2 is a negative regulator of the p53 pathway and is often overexpressed in cancer cells4,5,6,7,8,9. Recent crystallographic and biochemical studies have revealed that small molecules containing a spirocyclic framework can effectively inhibit MDM2-p53 interactions10. The spirocyclic framework (Figure 1, shaded in blue) is considered a privileged motif as derivatization of this rigid orthogonal ring system has led to the discovery of novel therapeutic drugs. Accessing this interesting architecture poses a challenge when using traditional organic synthesis techniques. Although the therapeutic effects of spirocyclic molecules in biological systems have been investigated, synthesis of these molecules is still a cumbersome process. Unwanted side products, using harsh conditions, and hazardous transition metals are often problematic.
The potential use of the spirocyclic motif in drug development led to the development of a protocol utilizing solid-phase synthesis to generate a library of molecules with the motif in addition to other interchangeable functional groups11,12. The separation of products and reactants between steps could be achieved by simply utilizing an REM linker attached to a resin bead and a solid-phase filter vessel. This would cut down steps and potentially increase yields. This synthetic approach could produce a large array of potential drug candidates. However, the effectiveness of these molecules in a biological system would require further investigation.
To determine the cytotoxicity of these spirocyclic compounds, the MTT assay13,14 was employed. This method measures cell viability and can be used to indirectly determine cell cytotoxicity. Different concentrations of the inhibitors were added to cultured cells in a 96-well plate, and the proportion of living cells was measured by colorimetric analysis of the extent of reduction of yellow MTT by mitochondrial dehydrogenases to the purple formazan compound (Figure 2). The activity is most often reported as an IC50 value-the concentration at which cell growth is inhibited by 50% relative to an untreated control. This paper describes the protocol for the MTT assay and the preliminary results of these novel spirocyclic molecules.

<table><tbody><tr><td>&lt;strong&gt;CELLS&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>COS-7 cells (ATCC CRL-1651)</td><td>ATCC</td><td>CRL-1651</td><td>African green monkey kidney cells</td></tr><tr><td>&lt;strong&gt;CHEMICALS&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>1-Bromooctane</td><td>Sigma-Aldrich</td><td>152951</td><td>Alkyl-halide</td></tr><tr><td>Allylbromide</td><td>Sigma-Aldrich</td><td>337528</td><td>Alkyl-halide</td></tr><tr><td>Benzylbromide</td><td>Sigma-Aldrich</td><td>B17905</td><td>Alkyl-halide</td></tr><tr><td>Cisplatin</td><td>Cayman Chemical</td><td>13119</td><td>Cytotoxicity control</td></tr><tr><td>Dichloromethane (DCM)</td><td>Sigma-Aldrich</td><td>270997</td><td>Solvent</td></tr><tr><td>Dimethylformamide (DMF)</td><td>Sigma-Aldrich</td><td>227056</td><td>Solvent</td></tr><tr><td>Dimethylsulfoxide (DMSO)</td><td>Sigma-Aldrich</td><td>276855</td><td>Solvent</td></tr><tr><td>DMEM, high glucose, with L-glutamine</td><td>Genesee Scientific</td><td>25-500</td><td>Cell culture media</td></tr><tr><td>FBS (Fetal bovine serum)</td><td>Sigma-Aldrich</td><td>F4135</td><td>Cell culture media</td></tr><tr><td>Furfurylamine</td><td>Acros Organics</td><td>119800050</td><td>reagent&amp;nbsp;</td></tr><tr><td>Iodomethane</td><td>Sigma-Aldrich</td><td>289566</td><td>Alkyl-halide</td></tr><tr><td>Methanol</td><td>Sigma-Aldrich</td><td>34860</td><td>Solvent</td></tr><tr><td>MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)</td><td>EMD Millipore</td><td>Calbiochem 475989-1GM</td><td>Reagent</td></tr><tr><td>Phosphate-buffered Saline (PBS)</td><td>Genesee Scientific</td><td>25-507</td><td>Cell culture media</td></tr><tr><td>REM Resin</td><td>Nova Biochem</td><td>8551010005</td><td>Polymer support; 0.500 mmol/g loading</td></tr><tr><td>&lt;em&gt;trans&lt;/em&gt;-&amp;beta;-nitrostyrene</td><td>Sigma-Aldrich</td><td>N26806</td><td>Nitro-olefin reagent</td></tr><tr><td>Toluene</td><td>Sigma-Aldrich</td><td>244511</td><td>Solvent</td></tr><tr><td>Triethylamine (TEA)</td><td>Sigma-Aldrich</td><td>T0886</td><td>Reagent for beta-elimination</td></tr><tr><td>Trimethylsilyl chloride (TMSCl)</td><td>Sigma-Aldrich</td><td>386529</td><td>Reagent; CAUTION - highly volatile; creates HCl gas</td></tr><tr><td>&lt;strong&gt;GLASSWARE/INSTRUMENTATION&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>25 mL solid-phase reaction vessel</td><td>Chemglass</td><td>CG-1861-02</td><td>Glassware with filter</td></tr><tr><td>96 Well plate reader</td><td>Promega (Turner Biosystems)</td><td>9310-011</td><td>Instrument</td></tr><tr><td>AVANCE III NMR Spectrometer</td><td>Bruker</td><td>N/A</td><td>Instrument; 300 MHz; Solvents: CDCl3 and CD3OH</td></tr><tr><td>Thermo Scientific Nicole iS5</td><td>Thermo Scientific</td><td>IQLAADGAAGFAHDMAZA</td><td>Instrument</td></tr><tr><td>Wrist-Action Shaker</td><td>Burrell Scientific</td><td>757950819</td><td>Instrument</td></tr></tbody></table>

functionalized spirocyclic heterocycle synthesis and cytotoxicity assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Spirocyclic heterocycles have recently been reported in literature to be potential drugs for cancer therapy. The synthesis of these novel orthogonal ring systems is challenging. An efficient methodology to synthesize these compounds was recently published that described the solid phase synthesis in four steps rather than the previously reported five steps. The advantage of this shorter synthesis is the elimination of the use of toxic reagents. Low-loading Regenerating Michael (REM) linker-based resin was found to be crucial in the synthesis as high-loading versions prevented the addition of reagents containing bulky phenyl and aromatic side chains. The colorimetric 3-(4&#8242;,5&#8242;-dimethylthiazol-2&#8242;-yl)-2,5- diphenyltetrazolium bromide (MTT) assay was used to examine the cytotoxicity of micromolar concentrations of these novel spirocyclic molecules in vitro. MTT is readily available commercially and produces relatively fast, reliable results, making this assay ideal for these spirocyclic heterocycles. Orthogonal ring structures as well as furfurylamine (a precursor in the synthesis method containing a similar 5-member ring motif) were tested.

Spirocyclic oximes 6 and 7 were synthesized using a modified protocol (Figure 1). Michael addition of furfurylamine to an REM linker 1b afforded polymer-bound resin 2. The progress of the reaction was monitored by infrared (IR) spectroscopy by detecting the disappearance of the α,β-unsaturated ester at 1722 cm-1 (Figure 3). Spirocyclic-bound resin 4 was formed from 2 via a transient intermediate 3. Methanolic hydrolysis of 4 produced 3-[(3E)-...

Here, we describe a bioassay using 3-(4&#8242;,5&#8242;-dimethylthiazol-2&#8242;-yl)-2,5- diphenyltetrazolium bromide (MTT) to test previously synthesized spirocyclic oximes.

Spirocyclic heterocycles have recently been reported in literature to be potential drugs for cancer therapy. The synthesis of these novel orthogonal ring ...

functionalized-spirocyclic-heterocycle-synthesis-cytotoxicity

Research

JoVE Journal

Biology

A method for synthesis of air-sensitive titanium and vanadium anticancer agents is described, along with the evaluation of their cytotoxic activity towards human cancer cell line by the MTT Assay.

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

A two-step procedure for the synthesis of pharmaceutically active indole-derivatives by C-H functionalization with anilines is described, using photo- and Brønsted acid catalysis.

Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides (CHIPS)

Here we present a protocol to demonstrate an efficient method for the synthesis of spirocyclic heterocycles. The five-step process utilizes solid-phase synthesis and regenerating Michael linker strategies. Generally difficult to synthesize, we present a customizable method for the synthesis of spirocyclic molecules otherwise inaccessible to other modern approaches.

Solid-phase Synthesis of [4.4] Spirocyclic Oximes

Enantiomerically enriched bispiro[γ-butyrolactone-pyrrolidin-4,4'-pyrazolone] skeletons are asymmetrically synthesized through a simple organocatalytic 1,3-dipolar cycloaddition reaction.

Efficient Construction of Drug-like Bispirocyclic Scaffolds Via Organocatalytic Cycloadditions of &#945;-Imino &#947;-Lactones and Alkylidene Pyrazolones

A protocol for the synthesis and measurement of the photochemical properties of modular caged compounds with clickable moieties is presented.

Design, Synthesis, and Photochemical Properties of Clickable Caged Compounds

New routes for the synthesis of nitrogen-containing heterocycles utilizing cercosporin as a metal-free photocatalyst were developed.

Cercosporin-Photocatalyzed [4+1]- and [4+2]-Annulations of Azoalkenes Under Mild Conditions

The Claisen-Schmidt condensation reaction is an important methodology for the generation of methine-bridged conjugated bicyclic aromatic compounds. Through utilizing a base-mediated variant of the aldol reaction, a range of fluorescent and/or biologically relevant molecules can be accessed through a generally inexpensive and operationally simple synthetic approach.

Synthesis of pH Dependent Pyrazole, Imidazole, and Isoindolone Dipyrrinone Fluorophores using a Claisen-Schmidt Condensation Approach

Thiophenesulfonamide compounds are potent and specific inhibitors of Vibrio quorum sensing regulators LuxR/HapR that block their activity in vivo, thus preventing transcription of genes for virulence, motility, and biofilms. This protocol details how these compounds are synthesized, modeled in silico, and assayed in vivo for activity against LuxR/HapR.

Synthesis and Assay of Vibrio Quorum Sensing Inhibitors

Here, we present a protocol for the structure-guided design of protein-ligand binding interaction between Sanglifehrin A and Cyclophilin A/Ganoderiol-F, essential in discovering new drugs. The stability of the ligand-receptor complex was evaluated using molecular dynamics simulation.

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

This protocol introduces a fluorometric screening methodology optimized for identifying natural product/small molecule inhibitors of protein synthesis. Its practicality makes it suitable for both undergraduate instruction in drug discovery techniques and implementation in medicinal chemistry campaigns.

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

Here, we present a protocol to identify potential anti-tuberculosis drug candidates through phenotypic screening, encompassing the chemical synthesis of a 4-aminoquinoline compound, determination of its minimum inhibitory concentration against Mycobacterium tuberculosis, and assessment of its cytotoxicity in mammalian cell lines.

Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells

Learn solid phase synthesis of spirocyclic heterocycles and cytotoxicity assessment using MTT assay on COS7 cells. This method evaluates novel compounds for cancer drug development.

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Explore More Videos